Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > October 8, 2020
Daily News
October 8, 2020
- Sumitomo Dainippon Rejigs Organization to Become Top CNS Player in Japan, Sets 50 Billion Yen Near-Term Goal
October 8, 2020
- Japan Ethical Drug Sales Dip 9.0% in August: Crecon
October 8, 2020
- Pfizer, Merck Biopharma to End Xalkori Copromotion in Japan
October 8, 2020
- CEFP Members Call for Tapping CPTPP Trade Deal for Joint Drug Manufacturing
October 8, 2020
- Elite Team Working to Secure COVID-19 Vaccines; Indemnity to Be a Major Focus: Ex-MHLW Chief Medical Officer
October 8, 2020
- Don’t Politicize Coronavirus Vaccine Introduction: Drug Damage Watchdog
October 8, 2020
- Fujifilm to Expand Viral Vector CDMO Biz to Europe
October 8, 2020
- Hisamitsu Initiates Japan PIII of Palmar Hyperhidrosis Drug, Aims at Filing in FY2022
October 8, 2020
- 1 More Soft Bag Product Recalled Over Flawed Testing at Kyowa CritiCare
October 8, 2020
- HUYA Files Novel T-Cell Leukemia-Lymphoma Med in Japan
October 8, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…